PYPD
PolyPid Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$5.61
+2.75%Oct 29, 2026, 12:00 UTC
PolyPid announced that it will report its third-quarter 2026 financial results and operational highlights before U.S. markets open on November 11, 2026.
Source:Oct 28, 2026, 12:00 UTC
PolyPid introduced PD01B, a Kynatrix-based product candidate for localized, controlled-release antibiotic treatment of diabetic foot infections.
Source:Oct 28, 2026, 12:00 UTC
PolyPid said it expects a pre-IND meeting and first-in-human study for PD01B in the second half of 2027.
Source:Oct 21, 2026, 12:00 UTC
PolyPid Ltd. will present D-PLEX₁₀₀ microbiology data at IDWeek 2026.
Source:Oct 17, 2026, 06:00 UTC
Hunger Pangs filed a draft prospectus for an IPO comprising a fresh issue of equity shares worth Rs 150 crore and an offer for sale of up to 2.79 crore shares by existing shareholders.
Oct 15, 2026, 12:30 UTC
PolyPid Ltd. announced that it will host a virtual investor day on October 28, 2026, to outline its long-term vision and pipeline strategy, with Warren S. Joseph, DPM, FIDSA, featured.
Source:Oct 1, 2026, 13:15 UTC
The European Medicines Agency validated PolyPid's Marketing Authorization Application for D-PLEX₁₀₀.
Source:Oct 1, 2026, 12:56 UTC
PolyPid and ADVANZ PHARMA mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe, returning European commercialization rights to PolyPid.
Source: